|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||201.26 - 204.73|
|52-week range||201.26 - 204.73|
|Beta (5Y monthly)||0.71|
|PE ratio (TTM)||16.96|
|Earnings date||03 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
(Bloomberg) -- Hummingbird Bioscience, a Singaporean clinical-stage biotechnology firm, is considering fundraising options including an initial public offering, according to people familiar with the matter.The company is interviewing investment banks as it weighs alternatives, which also include a private funding round, the people said, asking not to be identified because the matter is private.Hummingbird could seek to raise about $200 million to $300 million in a share sale, which could take pl
If you want to know who really controls Amgen Inc. ( NASDAQ:AMGN ), then you'll have to look at the makeup of its share...
Does the June share price for Amgen Inc. ( NASDAQ:AMGN ) reflect what it's really worth? Today, we will estimate the...